Danuglipron
Sources
registry, as of 2025-08-06Stale
https://clinicaltrials.gov/study/NCT06567327
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 82. Conditions Obesity. The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * if the study medicine, danuglipron, changes
ClinicalTrials.gov NCT06567327 protocol and results modules
registry, as of 2025-01-20Stale
https://clinicaltrials.gov/study/NCT06568731
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 23. Conditions Obesity. The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danugl
ClinicalTrials.gov NCT06568731 protocol and results modules
publication, as of 2025-08-06Stale
https://pubmed.ncbi.nlm.nih.gov/40539310/
to assess the efficacy, safety, and tolerability of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity. Eligible participants (aged 18-75 years; with obesity, without diabetes) were randomized to receive danuglipron or placebo
PMID 40539310